Physician profile
Marilyn E Conlon
NPI 1548373186
$4,578.59
in general payments reported to CMS, 2019-2025
22 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $518 · 2021: $696 · 2022: $1,028 · 2023: $330 · 2024: $542 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $967.34 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $578.21 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $487.81 | 2019-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $424.52 | 2019-2024 | Ingrezza |
| Lundbeck LLC | $383.31 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $243.66 | 2021-2022 | |
| Indivior INC. | $212.08 | 2019-2025 | Sublocade |
| Alkermes, INC. | $195.14 | 2021-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $189.61 | 2019-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $177.36 | 2020-2024 | Austedo Xr |
| Abbvie INC. | $170.99 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $119.50 | 2025 | Cobenfy |
| Eisai INC. | $109.91 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $79.80 | 2019-2022 | |
| Orexo US, INC. | $51.09 | 2019-2025 | Zubsolv |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $39.40 | 2021-2022 | |
| Brainsway USA INC | $35.90 | 2021-2022 | |
| Axsome Therapeutics, INC. | $25.72 | 2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.04 | 2025 | Rexulti |
| Allergan, INC. | $24.01 | 2020 | |
| Neuronetics, INC. | $23.59 | 2023 | Neurostar Tms Therapy System |
| Shire North American Group INC | $15.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn Conlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.